Radiesse works in two stages: a carrier gel that adds volume the same day, then calcium hydroxylapatite particles left behind as a scaffold that the body builds collagen around. It is a mineral suspension, not a hyaluronic acid gel — and that difference decides what can be done later if the result is wrong.
Its US approvals are area by area, because fillers go through the FDA's premarket approval route, which requires clinical evidence for a named cosmetic indication in a named place.
The one that matters here is supplement P050052/S129, approved 1 September 2021, a Panel Track supplement — the most demanding category, requiring new clinical data. The indication reads:
"RADIESSE (+) Lidocaine injectable implant is indicated for deep injection (subdermal and/or supraperiosteal) for soft tissue augmentation to improve moderate to severe loss of jawline contour in adults over the age of 21."
Read what that sentence contains and what it does not. It names jawline contour. It specifies deep placement, against or near the bone. It says soft tissue augmentation — adding volume. It does not say jowls, and it does not say lifting, tightening or laxity.
Radiesse's other named areas are facial wrinkles and folds such as nasolabial folds (2006), facial fat loss in people with HIV (2006), the backs of the hands (2015), and the décolleté at a 1:2 dilution (2026).
A jowl is soft tissue — fat and skin — that has slipped downward past the jaw margin, so the clean line of the jaw is interrupted by a bulge in front of it. Loss of jawline contour is a different observation: the bony framework and the tissue over it have flattened, so there is no crisp border between face and neck.
They often occur together, and the same face can have both. They are not the same problem and they do not have the same solution.
Filler placed deep along the mandible restores projection to the jaw line itself. Placed in front of and above a jowl, it can blunt the step-off so the eye reads a straighter line. What it does not do is lift the tissue that has descended. Nothing in the Radiesse label, and nothing in the endpoint of its jawline trial, involves lifting, tightening or repositioning tissue. The trial measured contour on a jawline scale.
Where a jowl is mostly loose skin, adding volume can make it heavier rather than better: That is the honest limit, and the reason a consultation should start by working out which of the two problems predominates. Treatments aimed at lax skin and descent — energy devices, threads, surgery — belong to a different category with their own evidence and their own risks.
Injecting Radiesse into the jowl itself is off-label. That is legal and routine, and it is not a mark against the injector. It is simply the reason there is no trial to quote for it.
The evidence the FDA reviewed for the 2021 approval is the strongest Radiesse data in this region, and it is worth knowing exactly what it showed.
**Primary endpoint at week 12: 75.6% responders, against 8.8% in the control group.**
At week 48, roughly 67.3% of the initial responders still met the definition of treatment success.
The study's final timepoint was week 60.
The most common treatment-related side effect was injection-site mass in 10.9%, followed by bruising and pain at 6.9% each. There were no treatment-related serious adverse events. One person had severe swelling lasting 16 days.
Skin types: Fitzpatrick I to III 60.6%, IV to VI 39.4% — the most skin-tone-diverse of the Radiesse pivotal trials, which is worth noting because most filler trials are heavily skewed to lighter skin.
The sponsor was Merz North America, which makes Radiesse. Registration trials are almost always run by the manufacturer; that does not invalidate them, but it belongs in the same sentence as the numbers.
There is no equivalent trial for jowls: The one published study that measured jowl volume after Radiesse used hyperdilute product across the mid and lower face and found reduced jowl volume on 3D imaging at day 150 (p<0.0001) in 22 charts - a retrospective review with no control group, graded Level of Evidence 4 by its own authors, from an author group with Merz ties, at a dilution that is not part of any approved labelling.
Merz markets Radiesse (+) as the "first and only aesthetic injectable to improve moderate to severe loss of jawline contour." That is the manufacturer's claim about its own indication wording, and it should be read as one.
Hyaluronic acid fillers can be broken down with hyaluronidase. Radiesse cannot. The enzyme has no chemical target in calcium hydroxylapatite microspheres or in the cellulose gel that carries them. There is no approved reversal agent for it, its label names none, and a 2026 review of the material lists the absence of one as a known limitation.
Sodium thiosulfate is sometimes named as a solution. It is not an established reversal agent for Radiesse; the published evidence for and against it is set out on the page about whether Radiesse is permanent.
If a jawline result is too heavy, too wide or asymmetric, the realistic options are time, saline injection with mechanical disruption through a cannula for a discrete nodule, intralesional steroid for an inflammatory lump, and rarely surgery. The label states that safety beyond 3 years in the face has not been investigated — a study window, not a lifespan.
Compare that with Juvederm Volux XC, approved on 29 July 2022 for "improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition." It is a hyaluronic acid gel, so it can be dissolved. Its trial reported 69.9% responders at month 6 against 39.1% in the delayed-treatment control group — and that control figure is worth noticing, because a 39.1% "response" in people who received nothing tells you how soft these scales can be. Volux is not approved for jowls either, and the two products' separate trials cannot be used to say one outperformed the other.
Questions worth asking at a consultation:
Is my problem loss of jaw definition, descended tissue, or both — and in what proportion?
If it is mostly loose skin, is filler the right category of treatment at all?
Where exactly are you placing product, and how much?
Why Radiesse rather than a filler that could be dissolved if I dislike it?
What happens if the result looks heavy from the side?
Go to an emergency department or call 911 for any of these, during or after the appointment. They can indicate filler in a blood vessel, and time matters in hours.
Any change in vision — blurring, a dark area, double vision or loss of sight in either eye
Sudden severe pain, or pain out of proportion to the procedure
Skin turning white or pale (blanching), then dusky, purple or mottled
Weakness, facial droop, slurred speech or any other stroke-like symptom
Swelling is still increasing after the first few days rather than settling
A firm lump forms and does not settle, or one appears weeks or months later
Redness spreads out from the injection site, or the area becomes warm and tender
Tenderness or swelling appears weeks after treatment, which can indicate a delayed inflammatory reaction or an infection
The contour looks like it has moved or become uneven